Allopurinol as add-on treatment for mania symptoms in bipolar disorder: Systematic review and meta-analysis of randomised controlled trials

British Journal of Psychiatry

Volumn 210, Issue 1, 2017, Pages 10-15

  Bartoli, Francesco ^a   Crocamo, Cristina ^a   Clerici, Massimo ^a   Carra, Giuseppe ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ENZYME INHIBITOR; TRANQUILIZER;

ADD ON THERAPY; ADJUVANT THERAPY; ASTHENIA; BIPOLAR DISORDER; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; MANIA; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; DRUG POTENTIATION;

ALLOPURINOL; ANTIMANIC AGENTS; BIPOLAR DISORDER; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85009135944     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.115.180281     Document Type: Review

References (32)

1. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58: 87-114.
2. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J Clin Psychopharmacol 2001; 21: 621-2.
3. Ortiz R, Ulrich H, Zarate CA, Machado-Vieira R. Purinergic system dysfunction in mood disorders: A key target for developing improved therapeutics. Prog Neuropsychopharmacol Biol Psychiatry 2015; 57: 117-31.
4. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Purinergic dysfunction in mania: An integrative model. Med Hypotheses 2002; 58: 297-304.
5. Salvadore G, Viale CI, Luckenbaugh DA, Zanatto VC, Portela LV, Souza DO, et al. Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 819-21.
6. Albert U, De Cori D, Aguglia A, Barbaro F, Bogetto F, Maina G. Increased uric acid levels in bipolar disorder subjects during different phases of illness. J Affect Disord 2015; 173: 170-5.
7. De Berardis D, Conti CM, Campanella D, Carano A, Di Giuseppe B, Valchera A, et al. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J Biol Regul Homeost Agents 2008; 22: 195-200.
8. Muti M, Del Grande C, Musetti L, Marazziti D, Turri M, Cirronis M, et al. Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium. Psychiatry Res 2015; 225: 604-8.
9. Kesebir S, Tatldil Yaylac E, Suner O, Gultekin BK. Uric acid levels may be a biological marker for the differentiation of unipolar and bipolar disorder: The role of affective temperament. J Affect Disord 2014; 165: 131-4.
10. Alda M. Lithium in the treatment of bipolar disorder: Pharmacology and pharmacogenetics. Mol Psychiatry 2015; 20: 661-70.
11. Shorter E. The history of lithium therapy. Bipolar Disord 2009; 11 (suppl 2): 4-9.
12. Hirota T, Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: A systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr Res 2013; 149: 88-95.
13. Jahangard L, Soroush S, Haghighi M, Ghaleiha A, Bajoghli H, Holsboer- Trachsler E, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder. Eur Neuropsychopharmacol 2014; 24: 1210-21.
14. Weiser M, Burshtein S, Gershon AA, Marian G, Vlad N, Grecu IG, et al. Allopurinol for mania: A randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder. Bipolar Disord 2014; 16: 441-7.
15. Sanches M, Newberg AR, Soares JC. Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs 2010; 15: 453-66.
16. Zarate CA, Manji HK. Putative drugs and targets for bipolar disorder. Mt Sinai J Med 2008; 75: 226-47.
17. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6: E1000097.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-35.
19. Schunemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Interpreting results and drawing conclusions. In Cochrane Handbook for Systematic Reviews of Interventions (eds JP Higgins, S Green). Cochrane Collaboration, 2008.
20. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: D5928.
21. Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. BMJ 2006; 332: 969-71.
22. Gupta SK. Intention-to-treat concept: A review. Perspect Clin Res 2011; 2: 109-12.
23. Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking metaanalyses. In Cochrane Handbook for Systematic Reviews of Interventions (eds JP Higgins, S Green). Cochrane Collaboration, 2008.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
25. Sterne JA, Egger M, Moher D. Addressing reporting biases. In Cochrane Handbook for Systematic Reviews of Interventions (eds JP Higgins, S Green). Cochrane Collaboration, 2008.
26. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: A double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006; 8: 485-9.
27. Fan A, Berg A, Bresee C, Glassman LH, Rapaport MH. Allopurinol augmentation in the outpatient treatment of bipolar mania: A pilot study. Bipolar Disord 2012; 14: 206-10.
28. Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008; 69: 1237-45.
29. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Erlbaum, 1988.
30. Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev 2014; 10: CD006077.
31. Ketter TA, Nasrallah HA, Fagiolini A. Mood stabilizers and atypical antipsychotics: Bimodal treatments for bipolar disorder. Psychopharmacol Bull 2006; 39: 120-46.
32. Bartoli F, Crocamo C, Gennaro GM, Castagna G, Trotta G, Clerici M, et al. Exploring the association between bipolar disorder and uric acid: A mediation analysis. J Psychosom Res 2016; 84: 56-9.